Elsevier

The Lancet Oncology

Volume 14, Issue 9, August 2013, Pages 882-892
The Lancet Oncology

Articles
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial

https://doi.org/10.1016/S1470-2045(13)70240-7Get rights and content

Summary

Background

Poly(ADP-ribose) polymerase (PARP) is implicated in DNA repair and transcription regulation. Niraparib (MK4827) is an oral potent, selective PARP-1 and PARP-2 inhibitor that induces synthetic lethality in preclinical tumour models with loss of BRCA and PTEN function. We investigated the safety, tolerability, maximum tolerated dose, pharmacokinetic and pharmacodynamic profiles, and preliminary antitumour activity of niraparib.

Methods

In a phase 1 dose-escalation study, we enrolled patients with advanced solid tumours at one site in the UK and two sites in the USA. Eligible patients were aged at least 18 years; had a life expectancy of at least 12 weeks; had an Eastern Cooperative Oncology Group performance status of 2 or less; had assessable disease; were not suitable to receive any established treatments; had adequate organ function; and had discontinued any previous anticancer treatments at least 4 weeks previously. In part A, cohorts of three to six patients, enriched for BRCA1 and BRCA2 mutation carriers, received niraparib daily at ten escalating doses from 30 mg to 400 mg in a 21-day cycle to establish the maximum tolerated dose. Dose expansion at the maximum tolerated dose was pursued in 15 patients to confirm tolerability. In part B, we further investigated the maximum tolerated dose in patients with sporadic platinum-resistant high-grade serous ovarian cancer and sporadic prostate cancer. We obtained blood, circulating tumour cells, and optional paired tumour biopsies for pharmacokinetic and pharmacodynamic assessments. Toxic effects were assessed by common toxicity criteria and tumour responses ascribed by Response Evaluation Criteria in Solid Tumors (RECIST). Circulating tumour cells and archival tumour tissue in prostate patients were analysed for exploratory putative predictive biomarkers, such as loss of PTEN expression and ETS rearrangements. This trial is registered with ClinicalTrials.gov, NCT00749502.

Findings

Between Sept 15, 2008, and Jan 14, 2011, we enrolled 100 patients: 60 in part A and 40 in part B. 300 mg/day was established as the maximum tolerated dose. Dose-limiting toxic effects reported in the first cycle were grade 3 fatigue (one patient given 30 mg/day), grade 3 pneumonitis (one given 60 mg/day), and grade 4 thrombocytopenia (two given 400 mg/day). Common treatment-related toxic effects were anaemia (48 patients [48%]), nausea (42 [42%]), fatigue (42 [42%]), thrombocytopenia (35 [35%]), anorexia (26 [26%]), neutropenia (24 [24%]), constipation (23 [23%]), and vomiting (20 [20%]), and were predominantly grade 1 or 2. Pharmacokinetics were dose proportional and the mean terminal elimination half-life was 36·4 h (range 32·8–46·0). Pharmacodynamic analyses confirmed PARP inhibition exceeded 50% at doses greater than 80 mg/day and antitumour activity was documented beyond doses of 60 mg/day. Eight (40% [95% CI 19–64]) of 20 BRCA1 or BRCA2 mutation carriers with ovarian cancer had RECIST partial responses, as did two (50% [7–93]) of four mutation carriers with breast cancer. Antitumour activity was also reported in sporadic high-grade serous ovarian cancer, non-small-cell lung cancer, and prostate cancer. We recorded no correlation between loss of PTEN expression or ETS rearrangements and measures of antitumour activity in patients with prostate cancer.

Interpretation

A recommended phase 2 dose of 300 mg/day niraparib is well tolerated. Niraparib should be further assessed in inherited and sporadic cancers with homologous recombination DNA repair defects and to target PARP-mediated transcription in cancer.

Funding

Merck Sharp and Dohme.

Introduction

Poly(ADP-ribose) polymerase (PARP) is a nuclear enzyme with dual roles in DNA repair and transcription regulation. PARP mediates DNA single-strand break repair through the base excision repair pathway. BRCA1 and BRCA2 proteins are crucial for homologous recombination—an accurate DNA double-strand break repair process. In the absence of BRCA and homologous recombination function, error-prone forms of DNA double-strand break repair predominate, which can increase a cell's mutational load and thereby lead to tumorigenesis. Although BRCA dysfunction promotes an oncogenic advantage, it also renders cancer cells reliant on base excision repair and hence susceptible to PARP inhibition.1, 2

Synthetic lethality is an association between two genes whereby defects in either gene are compatible with cell viability, but simultaneous defects in both genes result in cell death.1, 2 BRCA or homologous recombination has a synthetic lethal interaction with PARP. Therapeutic exploitation of this interaction via PARP inhibition in BRCA mutation carriers with cancer results in promising antitumour activity and has a favourable toxicity profile.2, 3, 4, 5, 6, 7 Broader clinical application of this synthetic lethality is the focus of continuing research; many sporadic (non-inherited) cancers (eg, prostate and high-grade serous ovarian cancers) harbour epigenetic and genetic disruption of genes that are crucial for the homologous recombination pathway, such as BRCA1, BRCA2, FANC, ATM, CHEK2, MRE11A, and RAD51.8, 9, 10, 11, 12, 13, 14, 15

Aside from its role in DNA damage response, PARP has been implicated in transcription regulation of the androgen receptor (AR) and rearranged erythroblast transformation-specific genes, such as ERG, ETV1, and FLI1.16, 17, 18 PARP inhibitors have antitumour activity in preclinical models of TMPRSS2-ERG rearranged prostate cancer and EWS-FLI1 rearranged Ewing's sarcoma.16, 17, 18 Additionally, PARP inhibitors suppress AR target-gene expression and tumour proliferation.19 Several studies are assessing PARP inhibitors in prostate cancer and sarcoma on the basis of this emerging therapeutic rationale (NCT01576172; NCT01682772; NCT01583543).

Niraparib (MK4827) is an orally bioavailable PARP-1 and PARP-2 inhibitor, with a half maximum inhibitory concentration (IC50) of 3·8 nmol/L for PARP-1 and 2·1 nmol/L for PARP-2.20 It inhibits tumour growth in models with loss of BRCA and PTEN function.21 We investigated the safety, tolerability, dose-limiting toxic effects (DLTs), maximum tolerated dose (MTD), and pharmacokinetic and pharmacodynamic profiles of niraparib. Additionally, we aimed to assess preliminary antitumour activity in carriers of BRCA1 and BRCA2 mutations and patients with high-grade serous ovarian cancer and prostate cancer.6, 9, 10, 11, 12, 13, 14, 15, 16, 22, 23

Section snippets

Participants

We undertook a two-part, phase 1 dose-escalation study of niraparib at the Royal Marsden NHS Foundation Trust (Sutton, UK), H Lee Moffitt Cancer Center and Research Institute (Tampa, FL, USA), and the University of Wisconsin Carbone Cancer Center (Madison, WI, USA). Eligible patients had advanced solid malignancies; were not suitable to receive any established treatments; were aged at least 18 years; had a life expectancy of at least 12 weeks; had an Eastern Cooperative Oncology Group

Results

Between Sept 15, 2008, and Jan 14, 2011, we enrolled 100 patients: 60 in part A and 40 in part B (figure 1). Table 1 shows patient characteristics. No major differences in participants or outcomes were reported across the three sites (data not shown).

569 cycles were administered (median per participant three [range one to 29]), at ten dose levels ranging from 30 mg/day to 400 mg/day (figure 1, table 2). Overall, four DLTs were recorded in the first cycle (table 2). At 30 mg/day, one of six

Discussion

We have shown that niraparib—an oral potent, selective PARP-1 and PARP-2 inhibitor—has favourable pharmacokinetics, inhibits PARP activity, is well tolerated up to the recommended phase 2 dose of 300 mg/day, and has antitumour activity in carriers of BRCA1 and BRCA2 mutations and patients with sporadic cancers. Non-haematological toxic effects were mild in severity and manageable. Grade 4 thrombocytopenia was dose limiting at 400 mg/day. In all cases, myelosuppression was self-limiting,

References (35)

  • TA Yap et al.

    Poly(ADP-ribose) polymerase (PARP) inhibitors: exploiting a synthetic lethal strategy in the clinic

    CA Cancer J Clin

    (2011)
  • CJ Lord et al.

    The DNA damage response and cancer therapy

    Nature

    (2012)
  • PC Fong et al.

    Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

    N Engl J Med

    (2009)
  • PC Fong et al.

    Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval

    J Clin Oncol

    (2010)
  • J Ledermann et al.

    Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer

    N Engl J Med

    (2012)
  • Integrated genomic analyses of ovarian carcinoma

    Nature

    (2011)
  • C Loveday et al.

    Germline mutations in RAD51D confer susceptibility to ovarian cancer

    Nat Genet

    (2011)
  • Cited by (467)

    • PARP inhibitors for prostate cancer

      2023, Seminars in Oncology
    View all citing articles on Scopus
    View full text